18.24
price up icon7.29%   1.24
pre-market  Pre-market:  18.33   0.09   +0.49%
loading
Beam Therapeutics Inc stock is traded at $18.24, with a volume of 3.28M. It is up +7.29% in the last 24 hours and down -21.72% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$17.00
Open:
$16.78
24h Volume:
3.28M
Relative Volume:
1.63
Market Cap:
$1.70B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-10.08
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+7.29%
1M Performance:
-21.72%
6M Performance:
-21.21%
1Y Performance:
-23.68%
1-Day Range:
Value
$16.66
$19.48
1-Week Range:
Value
$16.04
$19.48
52-Week Range:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Name
Beam Therapeutics Inc
Name
Phone
857-327-8775
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
483
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
18.24 1.70B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-28-25 Upgrade BofA Securities Neutral → Buy
Mar-10-25 Upgrade Scotiabank Sector Perform → Sector Outperform
Jan-29-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-06-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Jul-23-24 Initiated H.C. Wainwright Buy
Jan-29-24 Upgrade JP Morgan Neutral → Overweight
Dec-15-23 Downgrade BofA Securities Buy → Neutral
Dec-08-23 Downgrade Jefferies Buy → Hold
Oct-20-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Oct-20-23 Downgrade Leerink Partners Outperform → Market Perform
Mar-21-23 Initiated Bernstein Mkt Perform
Feb-01-23 Initiated Cantor Fitzgerald Overweight
Dec-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-13-22 Initiated Citigroup Buy
Jun-17-22 Initiated BMO Capital Markets Market Perform
Apr-28-22 Initiated Credit Suisse Neutral
Jan-05-22 Initiated Guggenheim Buy
Oct-19-21 Initiated SVB Leerink Outperform
Sep-24-21 Resumed Stifel Buy
Sep-10-21 Initiated BofA Securities Buy
May-11-21 Initiated Redburn Buy
May-04-21 Initiated RBC Capital Mkts Sector Perform
Mar-01-21 Downgrade Barclays Overweight → Equal Weight
Feb-16-21 Initiated Wells Fargo Overweight
Jan-29-21 Downgrade JP Morgan Overweight → Neutral
Jan-06-21 Initiated Stifel Hold
Aug-05-20 Initiated William Blair Outperform
Mar-02-20 Initiated Barclays Overweight
Mar-02-20 Initiated JP Morgan Overweight
Mar-02-20 Initiated Jefferies Buy
Mar-02-20 Initiated Wedbush Outperform
View All

Beam Therapeutics Inc Stock (BEAM) Latest News

pulisher
Apr 21, 2025

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga

Apr 21, 2025
pulisher
Apr 20, 2025

Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st

Apr 20, 2025
pulisher
Apr 14, 2025

How To Trade (BEAM) - news.stocktradersdaily.com

Apr 14, 2025
pulisher
Apr 12, 2025

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN

Apr 12, 2025
pulisher
Apr 11, 2025

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com

Apr 10, 2025
pulisher
Apr 08, 2025

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com

Apr 08, 2025
pulisher
Apr 08, 2025

Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com

Apr 08, 2025
pulisher
Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com

Apr 07, 2025
pulisher
Apr 07, 2025

H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com

Apr 07, 2025
pulisher
Apr 06, 2025

Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire

Apr 06, 2025
pulisher
Apr 05, 2025

Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq

Apr 05, 2025
pulisher
Apr 05, 2025

Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan

Apr 05, 2025
pulisher
Apr 04, 2025

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics president sells $136,418 in stock - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News

Apr 03, 2025
pulisher
Apr 02, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Apr 02, 2025
pulisher
Apr 01, 2025

Beam Therapeutics Becomes Oversold - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Apr 01, 2025
pulisher
Mar 31, 2025

8 Best Gene-Editing Stocks to Buy - Insider Monkey

Mar 31, 2025
pulisher
Mar 31, 2025

Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN

Mar 31, 2025
pulisher
Mar 29, 2025

Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus

Mar 29, 2025
pulisher
Mar 28, 2025

Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq

Mar 28, 2025
pulisher
Mar 28, 2025

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India

Mar 27, 2025

Beam Therapeutics Inc Stock (BEAM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Cap:     |  Volume (24h):